Actinium Pharmaceuticals, Inc. filed a third quarter 2026 corporate update on November 17, 2026, disclosing HER3 as the target of ATNM-400, reporting initial Phase 1/2a clinical findings from the HERACT-PRO-1 study in metastatic castration-resistant prostate cancer, and announcing the initiation of the RADIANZ pan-tumor imaging study.
Key Highlights
- HER3 target disclosed: Actinium announced HER3, an antigen described as distinct from PSMA and implicated in treatment resistance, as the target of ATNM-400.
- First cohort cleared 1.0 µCi/kg: The first cohort in HERACT-PRO-1 cleared the 1.0 µCi/kg dose level with no dose-limiting toxicities; dose escalation has advanced to 1.5 µCi/kg and is ongoing.
- RADIANZ study enrolling: The first patient was dosed in RADIANZ, a HER3 PET imaging study in advanced lung, breast, colorectal, pancreatic, and ovarian cancers.
- Cash position: Cash and cash equivalents were $28.7 million as of September 30, 2026, expected to fund operations through 2027.
- New CFO and SVP appointed: Matt David, M.D., was appointed Chief Financial Officer and Sean Maenpaa was appointed Senior Vice President, Business Development.
- Scientific Advisory Board formed: Five leading experts in prostate cancer, hematologic malignancies, radiochemistry, and nuclear medicine were appointed to a newly formed Scientific Advisory Board.
Actinium's Q3 2026 Update: ATNM-400 Clinical Progress and Pipeline Milestones
According to the filing, Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) reported third quarter 2026 corporate highlights centered on ATNM-400, an investigational antibody radioconjugate that pairs the HER3-targeting monoclonal antibody barecetamab with the alpha-emitting isotope Actinium-225. The company disclosed that initial data from the HERACT-PRO-1 Phase 1/2a study were presented at EANM 2026 and that the study was also featured at ESMO 2026. Imaging from HERACT-PRO-1 showed tumor uptake retained through Day 7, the filing stated.
The filing noted that Actinium initiated RADIANZ (Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89), a PET imaging study designed to guide pan-tumor development of ATNM-400 across solid tumors outside of prostate cancer. The company also reported that new preclinical data presented at EANM demonstrated antitumor activity across non-small cell lung cancer, colorectal, and ovarian cancer models, and that additional preclinical findings across breast cancer models are scheduled for presentation at SABCS 2026 on December 9, 2026.
On the corporate side, the filing disclosed that four abstracts from the Actimab-A and Iomab-ACT hematology programs were accepted for presentation at ASH 2026, scheduled for December 12-15. The company stated it expects to be operational with in-house manufacturing capabilities by around year-end. Actinium also announced a KOL webinar on ATNM-400 scheduled for December 1, 2026, at 8:00 a.m. ET, featuring Michael J. Morris, MD, Prostate Cancer Section Head at Memorial Sloan Kettering Cancer Center. The filing noted the company "continues to establish in-house manufacturing capabilities to support its clinical programs and expects to be operational by around year-end."
What Was Disclosed
Actinium Pharmaceuticals provided its third quarter 2026 corporate update disclosing ATNM-400's HER3 target, initial HERACT-PRO-1 clinical findings, initiation of the RADIANZ imaging study, new executive appointments, formation of a Scientific Advisory Board, and a cash position of $28.7 million as of September 30, 2026.




Please wait processing your request...